Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies.
The top two public health agencies in the United States conducted a joint study showing that the risk of developing autoimmune heart disease among the "fully vaccinated" for the Wuhan [.]
Researchers presented the results of their rapid cycle analysis safety surveillance, which is a weekly surveillance monitoring of monovalent mRNA COVID-19 vaccines among all children below five years enrolled in the Vaccine Safety Datalink (VSD).